KRAS and lung carcinoma: Across the panel of NSCLC lines, bosutinib reduced cell viability at micromolar IC50 of between 1–5 μM (Figure 2A and B) via apoptosis (Figure 2C) in all tested KRAS mutant and KRAS wild type (WT) lung cancer cell lines.